Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects

@article{Saisho2018PharmacokineticsSA,
  title={Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects},
  author={Yutaka Saisho and Takayuki Katsube and Scott White and Hiroyuki Fukase and Jingoro Shimada},
  journal={Antimicrobial Agents and Chemotherapy},
  year={2018},
  volume={62}
}
ABSTRACT Cefiderocol is a novel parenteral siderophore cephalosporin that shows potent efficacy against various Gram-negative bacteria, including carbapenem-resistant strains, in vitro and in preclinical models of infection. The aim of the present study was to evaluate the pharmacokinetics (PK), safety, and tolerability of cefiderocol after both single and multiple dosing by intravenous infusion over 60 min in healthy adult subjects. A single-ascending-dose study at doses of 100, 250, 500, 1… 
Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol
TLDR
Clinical efficacy trials indicated that cefiderocol is non-inferior to imipenem/cilastatin in the treatment of complicated urinary tract infections and acute uncomplicated pyelonephritis, and to meropenem in the Treatment of nosocomial pneumonia, suggesting that cffiderocol might be a viable option to treat infections with bacteria resistant to other antibiotics.
Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens
TLDR
A substantial body of evidence supports the clinical use of cefiderocol in patients with gram-negative infections and limited treatment options as well as the efficacy and safety data from the pivotal trials.
Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infection
TLDR
These study results support adequate plasma exposure can be achieved at the cefiderocol recommended dosing regimen for the infected patients, including the patients with augmented renal function, ventilation, and/or severe illness.
Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects
TLDR
Results of this study indicate that cefiderocol penetrates into ELF, and ELF and plasma concentrations appear to be parallel.
Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence
TLDR
It is shown that cefiderocol was a promising therapeutic agent in carbapenem-resistant infections and a promising powerful weapon for treating MDR recalcitrant infections.
Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters
TLDR
In vivo drug-drug interaction (DDI) potential of cefiderocol has no clinically significant DDI potential via drug transporters, and each treatment was well tolerated.
Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety
TLDR
The use of cefiderocol should be limited only to the treatment of cUTIs from Gram-negative bacteria, especially in patients who have limited or no alternative treatment options.
Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms
TLDR
The purpose of this article is to review existing data on the mechanism of action, microbiology, pharmacokinetics, pharmacodynamics, efficacy, and safety of cefiderocol to assist clinicians in determining its place in therapy.
Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data
TLDR
Cefiderocol is a siderophore cephalosporin recently approved by the Food and Drug Administration and European Medicines Agency that may have the potential to fill some of the remaining gaps in the treatment of MDR-GNB infections.
...
...

References

SHOWING 1-10 OF 24 REFERENCES
Cefiderocol, a Siderophore Cephalosporin for Gram‐Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment
TLDR
In conclusion, renal impairment impacted AUC, CL, and t1/2 without affecting Cmax, and cefiderocol was significantly removed by intermittent hemodialysis.
Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, for Dose Adjustment Based on Renal Function
TLDR
The PK of cefiderocol could be adequately modeled, and the modeling-and-simulation approach suggested dose regimens based on renal function, ensuring drug exposure with adequate bactericidal effect.
In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016
TLDR
It is concluded that cefiderocol demonstrated potent in vitro activity against a 2014–2016, worldwide collection of clinical isolates of carbapenem-nonsusceptible Enterobacteriaceae, MDR A. baumannii,MDR P. aeruginosa, S. maltophilia, and B. cepacia.
In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains
TLDR
This is the first report to demonstrate that S-649266, a novel siderophore cephalosporin, has significant antimicrobial activity against Enterobacteriaceae, including strains that produce carbapenemases such as KPC and NDM-1.
In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria.
TLDR
S-649266 is a novel antibiotic with potent in vitro activity against a range of non-fermenting Gram-negative bacteria, including MDR strains.
Current Epidemiology and Growing Resistance of Gram-Negative Pathogens
  • D. Livermore
  • Biology, Medicine
    The Korean journal of internal medicine
  • 2012
TLDR
Gram-negative isolates -both fermenters and non-fermenters-susceptible only to colistin and, more variably, fosfomycin and tigecycline, are encountered with increasing frequency, including in Korea.
Contribution of Efflux Pumps, Porins, and β-Lactamases to Multidrug Resistance in Clinical Isolates of Acinetobacter baumannii
TLDR
The absence of the AdeABC system and the lack of expression of other mechanisms suggest that tigecycline-resistant strains of the PFGE-HUI-1 clone may be associated with a novel resistance-nodulation-cell efflux pump.
Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004–2013
TLDR
Amikacin, the carbapenems, and tigecycline were active against most gram-negative pathogens while linezolid, tigelline, and vancomycin retained activity against most Gram-positive pathogens collected in TEST during 2004–2013.
Global dissemination of extensively drug‐resistant carbapenemase‐producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control
TLDR
A clinical perspective on the management of patients infected or colonized with CPE is provided and existing data support the use of combination therapy for treatment of severe infections caused by CPE.
Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries.
TLDR
Increasing MβL prevalence is worrisome in various European countries; however, intrinsic resistance mechanisms in a highly genetically diverse population of carbapenem-non-susceptible P. aeruginosa are probably a matter for greater concern in these countries.
...
...